Paper41007730
Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems.
Schreiner TG and 3 others. Biomedicines, 2025. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems. Papers, record 41007730. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007730
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References142
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36068427 | Approaches to Gene Modulation Therapy for ALS. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/36068427 | PubMed |
| 2 | 28780180 | Neuropathology of Parkinson disease. | Parkinsonism Relat Disord | 2018 | https://conductscience.org/library/papers/28780180 | PubMed |
| 3 | 35378156 | Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. | Int J Biol Macromol | 2022 | https://conductscience.org/library/papers/35378156 | PubMed |
| 4 | 37250416 | Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. | Front Neurosci | 2023 | https://conductscience.org/library/papers/37250416 | PubMed |
| 5 | 35563214 | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35563214 | PubMed |
| 6 | 27063658 | Cerebrospinal Fluid Dynamics and the Pathophysiology of Hydrocephalus: New Concepts. | Semin Ultrasound CT MR | 2016 | https://conductscience.org/library/papers/27063658 | PubMed |
| 7 | 39684197 | Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39684197 | PubMed |
| 8 | 35493843 | AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. | Front Neurol | 2022 | https://conductscience.org/library/papers/35493843 | PubMed |
| 9 | 21343917 | Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. | Mol Ther | 2011 | https://conductscience.org/library/papers/21343917 | PubMed |
| 10 | 27433993 | Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management. | Neuromodulation | 2016 | https://conductscience.org/library/papers/27433993 | PubMed |
| 11 | 29443664 | Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29443664 | PubMed |
| 12 | 31243392 | AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. | Gene Ther | 2019 | https://conductscience.org/library/papers/31243392 | PubMed |
| 13 | 35221289 | Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. | Drug Metab Dispos | 2022 | https://conductscience.org/library/papers/35221289 | PubMed |
| 14 | 32879313 | Circadian control of brain glymphatic and lymphatic fluid flow. | Nat Commun | 2020 | https://conductscience.org/library/papers/32879313 | PubMed |
| 15 | 36674643 | Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36674643 | PubMed |
| 16 | 38055260 | Tominersen in Adults with Manifest Huntington's Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/38055260 | PubMed |
| 17 | 39736972 | Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39736972 | PubMed |
| 18 | 38527856 | APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer's disease. | Brain | 2024 | https://conductscience.org/library/papers/38527856 | PubMed |
| 19 | 37302978 | GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy. | J Mov Disord | 2023 | https://conductscience.org/library/papers/37302978 | PubMed |
| 20 | 38294637 | Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review. | J Neurooncol | 2024 | https://conductscience.org/library/papers/38294637 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883972 | Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883972 | PubMed |
| 42793044 | Decoding MAPT Exon 10 Mis-Splicing in FTDP-17: From Pathogenic Mechanisms and Experimental Models to Molecular Therapies. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42793044 | PubMed |
| 42756044 | Therapeutic strategies in prion disease: current evidence, translational challenges, and emerging directions. | Front Neurosci | 2026 | https://conductscience.org/library/papers/42756044 | PubMed |
| 42738833 | Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases. | Cells | 2026 | https://conductscience.org/library/papers/42738833 | PubMed |
| 42667630 | Advanced Materials for Biologics Delivery to Brain Tumors. | Adv Mater | 2026 | https://conductscience.org/library/papers/42667630 | PubMed |
| 42633286 | SafeSense: An open-access safety atlas for antisense oligonucleotides adverse events in human. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42633286 | PubMed |
| 42576199 | ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities. | Cell Mol Biol Lett | 2026 | https://conductscience.org/library/papers/42576199 | PubMed |
| 42282541 | Lumbar intrathecal catheterization in rats targeting the cerebral cortex: a drug delivery method and validation. | bioRxiv | 2026 | https://conductscience.org/library/papers/42282541 | PubMed |
| 42279220 | Advanced Drug Delivery Strategies in Geriatric Patients with Polypharmacy: Integrating Pharmacokinetics, Personalized Medicine, and Emerging Technologies. | J Clin Med | 2026 | https://conductscience.org/library/papers/42279220 | PubMed |
| 42234836 | Peptide-Based Delivery Systems: Selected Insights into Cell-Penetrating Peptides. | ACS Chem Neurosci | 2026 | https://conductscience.org/library/papers/42234836 | PubMed |
| 42205472 | Variability in the circulation of cerebrospinal fluid: causes and clinical implications for intraventricular drug delivery. | Front Drug Deliv | 2026 | https://conductscience.org/library/papers/42205472 | PubMed |
| 42164918 | Toward nanomedicine-enabled RNA therapeutics for Alzheimer's disease. | Mol Neurodegener Adv | 2026 | https://conductscience.org/library/papers/42164918 | PubMed |
| 42147722 | Ultrasonic modulation of brain glymphatic transport: from observations to theranostic applications. | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42147722 | PubMed |
| 42076121 | Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42076121 | PubMed |
| 41828589 | From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828589 | PubMed |
| 41595696 | Screen, Sample, Stratify: Biomarkers and Machine Learning Compress Dementia Pathways. | Biomedicines | 2026 | https://conductscience.org/library/papers/41595696 | PubMed |
| 41462898 | Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer's Disease and Other Tauopathies. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462898 | PubMed |
| 41441314 | Parental Knowledge and Acceptance of Pediatric Lumbar Puncture in Northern Saudi Arabia: Implications for Clinical Practice and Education: A Cross-Sectional Study. | Pediatr Rep | 2025 | https://conductscience.org/library/papers/41441314 | PubMed |
| 41369342 | Orthobiologics and Peptide Therapy for Central Nervous System Repair in Neurodegenerative Conditions. | Cells | 2025 | https://conductscience.org/library/papers/41369342 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007730
GET https://conductscience.org/api/papers/v1/41007730/references?page=2